Wednesday, July 8, 2026

Patent intelligence · US

US 11684596

Antidiabetic pharmaceutical compositions and preparation method thereof

granted A61KA61K31/155A61K31/166A61K31/40
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 17
Applicant portfolio 26
Patent details — US 11684596
Jurisdiction
US
Status
granted
Grant date
Jun 27, 2023
Expiration
Jun 22, 2043
Claims
25
CPC classes
A61K, A61K31/155, A61K31/166, A61K31/40
View on Google Patents ↗

Quick answer

US 11684596 (Antidiabetic pharmaceutical compositions and preparation method thereof) is held by Elite Pharmaceutical Solution Inc.. Status: granted. Granted Jun 27, 2023. Expires Jun 22, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
25
CPC classes
A61K, A61K31/155, A61K31/166, A61K31/40, A61K31/403, A61K31/4162

More from Elite Pharmaceutical Solution Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12364693

    Methods of treating metabolic diseases with fused bicyclic pyrazoles

    Belite Bio, Inc · Expires Jul 17, 2045

    granted
  2. US 12295394

    Water-soluble additive composition

    SUMITOMO BAKELITE CO., LTD. · Expires May 8, 2045

    granted
  3. US 12116596

    Method and apparatus for improved mesenchymal stem cell harvesting

    Elite IP, LLC · Expires Oct 10, 2044

    granted
  4. US 12016853

    Methods of treating RBP4 related diseases with triazolopyridines

    Belite Bio, Inc · Expires Jun 20, 2044

    granted
  5. US 11951100

    Formulations of RBP4 inhibitors and methods of use

    Belite Bio, Inc · Expires Apr 4, 2044

    granted
  6. US 11723873

    Oral dosage form of ticagrelor and preparation method thereof

    Elite Pharmaceutical Solution Inc. · Expires Aug 10, 2043

    granted
  7. US 11655454

    Method and apparatus for improved mesenchymal stem cell harvesting

    Elite IP, LLC · Expires May 18, 2043

    granted

Frequently asked questions

What is US patent 11684596?

US 11684596 (Antidiabetic pharmaceutical compositions and preparation method thereof) is held by Elite Pharmaceutical Solution Inc.. Status: granted. Granted Jun 27, 2023. Expires Jun 22, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11684596?

Elite Pharmaceutical Solution Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.

When does US 11684596 expire?

Our index shows an expiration date of Jun 22, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.